Literature DB >> 18492116

Thromboelastography in children with coagulation factor deficiencies.

Meera Chitlur1, Indira Warrier, Madhvi Rajpurkar, Wendy Hollon, Lolita Llanto, Carol Wiseman, Jeanne M Lusher.   

Abstract

Hemophilia is traditionally classified according to the levels of the deficient coagulation factor as Severe (<1%), Moderate (1-5%) or Mild (>5%). However, it is well known that the factor activity does not necessarily correspond to the clinical bleeding manifestations. As prophylactic therapy is the best method of prevention of serious complications such as hemophilic arthropathy, a test that may predict the bleeding pattern would be extremely beneficial. Thromboelastography (TEG) uses whole blood to determine clot formation characteristics, such as initiation, propagation as well as strength of the clot, and is now being extensively studied in bleeding and thrombophilia. This study attempted to determine the TEG characteristics in 47 children with moderate hemophilia (MH) and severe hemophilia with (SHI) and without inhibitors (SH) and tried to retrospectively correlate them to the clinical bleeding patterns. TEG showed evidence of faster and better clot formation, as evidenced by a higher maximum thrombin/fibrin generation, in those with mild bleeding manifestations compared to those with severe bleeding tendency, in addition to the expected prolongation in time to formation of clot related to factor deficiency. This may be a potentially useful tool to evaluate the bleeding tendency and determine need for prophylaxis in children with hemophilia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18492116     DOI: 10.1111/j.1365-2141.2008.07063.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  A standardized technique for performing thromboelastography in rodents.

Authors:  Max V Wohlauer; Ernest E Moore; Jeffrey Harr; Eduardo Gonzalez; Miguel Fragoso; Christopher C Silliman
Journal:  Shock       Date:  2011-11       Impact factor: 3.454

Review 2.  Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future.

Authors:  Victor Jiménez-Yuste; Günter Auerswald; Gary Benson; Thierry Lambert; Massimo Morfini; Eduardo Remor; Silva Zupančić Salek
Journal:  Blood Transfus       Date:  2014-07       Impact factor: 3.443

Review 3.  Global coagulation assays: a clinical perspective.

Authors:  Ayesha Zia; Sarah H O'Brien
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

4.  A decreased and less sustained desmopressin response in hemophilia A carriers contributes to bleeding.

Authors:  Victoria Candy; Hilary Whitworth; Julie Grabell; Lisa Thibeault; Lori Harpell; Mackenzie Bowman; David Good; Wilma M Hopman; Robert F Sidonio; Paula D James
Journal:  Blood Adv       Date:  2018-10-23

5.  Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.

Authors:  R Stagaard; M J Flick; B Bojko; K Goryński; P Z Goryńska; C D Ley; L H Olsen; T Knudsen
Journal:  J Thromb Haemost       Date:  2018-06-21       Impact factor: 5.824

Review 6.  Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives.

Authors:  Guy Young; Benny Sørensen; Yesim Dargaud; Claude Negrier; Kathleen Brummel-Ziedins; Nigel S Key
Journal:  Blood       Date:  2013-01-14       Impact factor: 22.113

7.  Specific and global coagulation tests in patients with mild haemophilia A with a double mutation (Glu113Asp, Arg593Cys).

Authors:  Alenka Trampuš Bakija; Maruša Debeljak; Irena Preložnik Zupan; Majda Benedik Dolničar; Jernej Kovač; Janez Jazbec
Journal:  Blood Transfus       Date:  2015-05-15       Impact factor: 3.443

8.  Integration of acoustic radiation force and optical imaging for blood plasma clot stiffness measurement.

Authors:  Caroline W Wang; Matthew J Perez; Brian P Helmke; Francesco Viola; Michael B Lawrence
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

9.  Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype.

Authors:  Frank Driessler; Maricel G Miguelino; Glenn F Pierce; Robert T Peters; Jurg M Sommer
Journal:  Blood Coagul Fibrinolysis       Date:  2017-10       Impact factor: 1.276

10.  Clot stability as a determinant of effective factor VIII replacement in hemophilia A.

Authors:  L Leong; I N Chernysh; Y Xu; D Sim; C Nagaswami; Z de Lange; S Kosolapova; A Cuker; K Kauser; J W Weisel
Journal:  Res Pract Thromb Haemost       Date:  2017-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.